Belluscura (BELL) Competitors GBX 0.75 0.00 (0.00%) As of 08/21/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsBuy This Stock BELL vs. RUA, SUN, MHC, MXCT, DEMG, NIOX, SN, EKF, CREO, and IUGShould you be buying Belluscura stock or one of its competitors? The main competitors of Belluscura include RUA Life Sciences (RUA), Surgical Innovations Group (SUN), MyHealthChecked (MHC), MaxCyte (MXCT), Deltex Medical Group (DEMG), NIOX Group (NIOX), Smith & Nephew (SN), EKF Diagnostics (EKF), Creo Medical Group (CREO), and Intelligent Ultrasound Group (IUG). These companies are all part of the "medical devices" industry. Belluscura vs. Its Competitors RUA Life Sciences Surgical Innovations Group MyHealthChecked MaxCyte Deltex Medical Group NIOX Group Smith & Nephew EKF Diagnostics Creo Medical Group Intelligent Ultrasound Group Belluscura (LON:BELL) and RUA Life Sciences (LON:RUA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends. Do insiders & institutionals have more ownership in BELL or RUA? 6.3% of Belluscura shares are held by institutional investors. Comparatively, 26.0% of RUA Life Sciences shares are held by institutional investors. 56.3% of Belluscura shares are held by company insiders. Comparatively, 51.3% of RUA Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is BELL or RUA more profitable? RUA Life Sciences has a net margin of -65.72% compared to Belluscura's net margin of -1,030.73%. RUA Life Sciences' return on equity of -26.38% beat Belluscura's return on equity.Company Net Margins Return on Equity Return on Assets Belluscura-1,030.73% -102.62% -43.53% RUA Life Sciences -65.72%-26.38%-17.50% Which has more risk and volatility, BELL or RUA? Belluscura has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Comparatively, RUA Life Sciences has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500. Which has higher earnings and valuation, BELL or RUA? RUA Life Sciences has higher revenue and earnings than Belluscura. RUA Life Sciences is trading at a lower price-to-earnings ratio than Belluscura, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBelluscura£2.87M0.66-£29.55M-£9.37-0.08RUA Life Sciences£4.05M1.74-£2.66M-£4.29-2.65 Does the media prefer BELL or RUA? In the previous week, Belluscura's average media sentiment score of 0.00 equaled RUA Life Sciences'average media sentiment score. Company Overall Sentiment Belluscura Neutral RUA Life Sciences Neutral SummaryRUA Life Sciences beats Belluscura on 9 of the 11 factors compared between the two stocks. Get Belluscura News Delivered to You Automatically Sign up to receive the latest news and ratings for BELL and its competitors with MarketBeat's FREE daily newsletter. Email Address BELL vs. The Competition Export to ExcelMetricBelluscuraMedical Devices IndustryMedical SectorLON ExchangeMarket Cap£1.89M£3.59B£5.83B£3.22BDividend YieldN/A2.44%4.40%5.04%P/E Ratio-0.0878.0031.30164.70Price / Sales0.66100.78473.33310,111.42Price / Cash8.0015.9938.0227.93Price / Book0.063.919.535.91Net Income-£29.55M£132.05M£3.26B£5.89B7 Day PerformanceN/A1.22%2.14%49.52%1 Month PerformanceN/A0.37%2.81%56.36%1 Year Performance-93.15%9.08%30.70%136.20% Belluscura Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BELLBelluscuraN/AGBX 0.75flatN/AN/A£1.89M£2.87M-0.0824RUARUA Life SciencesN/AGBX 11.50-5.2%N/A+7.0%£7.14M£4.05M-2.6848Gap DownSUNSurgical Innovations GroupN/AGBX 0.66-5.7%N/A-4.9%£6.16M£12.54M-21.1180MHCMyHealthCheckedN/AGBX 10.80+2.9%N/A-3.2%£5.62M£9.43M-5.3916Gap UpMXCTMaxCyteN/AGBX 1.27-3.8%N/A-99.6%£1.68M£57.52M-0.0580High Trading VolumeDEMGDeltex Medical GroupN/AN/AN/AN/A£187K£1.76M-0.1537Gap UpHigh Trading VolumeNIOXNIOX GroupN/AGBX 67flatGBX 90+34.3%+2.4%£27.52B£3.53B2,764.9792SNSmith & Nephew2.4952 of 5 starsGBX 1,353flatGBX 1,379.33+1.9%+18.3%£14.83B£7.08B48.7118,452News CoverageInsider TradeHigh Trading VolumeEKFEKF DiagnosticsN/AGBX 29.80+2.9%N/A+1.5%£132.45M£49.91M27.73356Positive NewsCREOCreo Medical GroupN/AGBX 13.75+4.8%N/A-52.6%£55.59M£33.87M-2.18279IUGIntelligent Ultrasound GroupN/AN/AN/AN/A£42.76M£6.57M-18.9165 Related Companies and Tools Related Companies RUA Competitors SUN Competitors MHC Competitors MXCT Competitors DEMG Competitors NIOX Competitors SN Competitors EKF Competitors CREO Competitors IUG Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:BELL) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Belluscura plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Belluscura With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access